Sustainability Data Articles & Analysis: Older
3 news found
Outside the U.S., the Hydrus Microstent is routinely performed as a standalone MIGS procedure (in addition to concurrent with cataract surgery), and prior studies have shown a reduction in both intraocular pressure (IOP) and medication use.1 The Hydrus Microstent has also been shown to reduce peaks and fluctuations in the diurnal IOP curve.2 The FRONTIER trial will build on long-term findings ...
Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced 12-month results from a Level 1, prospective, randomized, multi-center trial that demonstrated the effectiveness and superiority of the Intracept® Procedure for vertebrogenic CLBP compared to standard care treatments. The INTRACEPT study randomized 140 ...
With the recent publication of our 5-year data showing sustained improvements in pain and function, we expect even greater adoption in 2021 as more and more physicians make Intracept a core part of their CLBP patient care pathway. ...